TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Schedule of Income Tax (Benefit)/Provision (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Current
Deferred	4,129,000	(5,914,000)
Change in Valuation Allowance	(4,129,000)	5,914,000
Income Tax Benefit

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.